{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:50:36Z","timestamp":1793893836404,"version":"4.8.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,21]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with follicular lymphoma who experience disease progression within 24 months of diagnosis (POD24) have a lower survival. Positron emission tomography (PET) response and circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at end of induction (EOI) may allow their early identification. A representative cohort of 141 patients from the RELEVANCE phase 3 trial with both available serum samples for ctDNA testing and PET images at randomization and at EOI (week 24) was investigated. Twelve percent were POD24. ctDNA was analyzed using a customized 130-kilobase capture panel, with phased variant (PV) enriched regions representing 39% of the panel. ctDNA was detected in 140 patients (99.3%) at baseline. To optimize specificity, only PVs, found in 124 patients (88%), were considered for ctDNA MRD assessment at EOI. Median progression-free survival (PFS) from EOI was not reached (NR) for the 112 patients with undetected ctDNA at EOI vs 17.7 months (95% confidence interval [CI], 1.4 to NR) for patients with positive ctDNA (MRD+) (P = .0038). Similarly, median PFS was NR for the 104 patients with undetected disease on PET at EOI vs 28.3 months (95% CI, 2.9 to NR; P = .0002) for patients with PET positivity. Both tests had a negative predictive value (NPV) of &amp;gt;90% for POD24. The positive predictive value was 58.3% for ctDNA MRD and 45% for PET but increased to 85.7% when both parameters were combined, without alteration of NPV. These data show that the combination of PET response and ctDNA MRD at EOI allows an early prediction of POD24, which may lead to a preemptive treatment decision. This trial was registered at www.clinicaltrials.gov as #NCT01650701.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024027727","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:24:10Z","timestamp":1749655450000},"page":"913-925","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-3930","authenticated-orcid":false,"given":"Alexis","family":"Claudel","sequence":"first","affiliation":[{"name":"1Department of Immunology Biology, Centre Hospitalier Universitaire Mondor, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Est, Creteil, Institut Mondor de Recherche Biomedicale, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-4564","authenticated-orcid":false,"given":"Anne-S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"additional","affiliation":[{"name":"2Department of Nuclear Medicine, H\u00f4pital Cochin, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-7510","authenticated-orcid":false,"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Lyon-Sud Hospital Center, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-4058","authenticated-orcid":false,"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[{"name":"4Department of Nuclear Medicine, Centre Hospitalier Universitaire Mondor, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Est, Creteil, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Centre Hospitalier R\u00e9gional Universitaire Nancy and INSERM 1256, Universit\u00e9 de Lorraine, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-7961","authenticated-orcid":false,"given":"Cedric","family":"Rossi","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Centre Hospitalier Universitaire de Dijon, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Lemonnier","sequence":"additional","affiliation":[{"name":"7Department of Lymphoid Malignancies, Centre Hospitalier Universitaire Mondor, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Est, Creteil, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-007X","authenticated-orcid":false,"given":"Vincent","family":"Camus","sequence":"additional","affiliation":[{"name":"8Department of Hematology, INSERM U1245, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Daguindau","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Centre Hospitalier Annecy Genevois, Metz-Tessy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"10Department of Hematology, University Hospital, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Centre L\u00e9on B\u00e9rard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9236-173X","authenticated-orcid":false,"given":"Diana-Laure","family":"Mboumba","sequence":"additional","affiliation":[{"name":"1Department of Immunology Biology, Centre Hospitalier Universitaire Mondor, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Est, Creteil, Institut Mondor de Recherche Biomedicale, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Cardoso","sequence":"additional","affiliation":[{"name":"1Department of Immunology Biology, Centre Hospitalier Universitaire Mondor, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Est, Creteil, Institut Mondor de Recherche Biomedicale, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5695-911X","authenticated-orcid":false,"given":"C\u00f4me","family":"Bommier","sequence":"additional","affiliation":[{"name":"12Department of Hematology, H\u00f4pital Saint-Louis, Centre Hospitalier Universitaire Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Centre Hospitalier Universitaire Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Fruchart","sequence":"additional","affiliation":[{"name":"14Department of Hematology, Centre Hospitalier de Dunkerque, Dunkerque, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Gilbert","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Institut Curie Saint Cloud et LITO, U1288, Saint Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-0089","authenticated-orcid":false,"given":"Eric","family":"Durot","sequence":"additional","affiliation":[{"name":"16Department of Hematology, H\u00f4pital Robert Debr\u00e9 Centre Hospitalier Universitaire de Reims, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Fleck","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Centre Hospitalier de La Rochelle, La Rochelle, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Matteo","family":"Pica","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Centre Hospitalier Chambery, Chambery, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacene","family":"Zerazhi","sequence":"additional","affiliation":[{"name":"19Department of Oncologie M\u00e9dicale et H\u00e9matologie Clinique, Centre Hospitalier Henri Duffaut, Avignon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Guidez","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Necker Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-9304","authenticated-orcid":false,"given":"Clementine","family":"Sarkozy","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Institut Curie Saint Cloud et LITO, U1288, Saint Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[{"name":"22Department of Pathology, Institut Paoli Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Vercellino","sequence":"additional","affiliation":[{"name":"23Department of Nuclear Medicine, H\u00f4pital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Trabelsi","sequence":"additional","affiliation":[{"name":"1Department of Immunology Biology, Centre Hospitalier Universitaire Mondor, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Est, Creteil, Institut Mondor de Recherche Biomedicale, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8824-8111","authenticated-orcid":false,"given":"Lucie","family":"Gomes","sequence":"additional","affiliation":[{"name":"24INSERM U918, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Portugues","sequence":"additional","affiliation":[{"name":"25Department of Biostatistics, Pierre-B\u00e9nite, LYSARC, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Julien","family":"Viailly","sequence":"additional","affiliation":[{"name":"24INSERM U918, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8010-2343","authenticated-orcid":false,"given":"Marie-H\u00e9l\u00e8ne","family":"Delfau-Larue","sequence":"additional","affiliation":[{"name":"1Department of Immunology Biology, Centre Hospitalier Universitaire Mondor, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris-Est, Creteil, Institut Mondor de Recherche Biomedicale, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"26Department of Hematology, Centre Hospitalier Universitaire Lille, University of Lille, ULR 7365, Groupe de Recherche sur les Formes Injectables et les Technologies Associ\u00e9es, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"31","key":"2025082111222144900_bib1","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025082111222144900_bib2","first-page":"105","article-title":"Current trends in diagnosis and management of follicular lymphoma","volume":"12","author":"Gupta","year":"2022","journal-title":"Am J Blood Res"},{"issue":"11","key":"2025082111222144900_bib3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025082111222144900_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/cam4.1918","article-title":"The prognostic significance of PFS24 in follicular lymphoma following first line immunotherapy: a combined analysis of 3 CALGB trials","volume":"8","author":"Lansigan","year":"2019","journal-title":"Cancer Med"},{"issue":"23","key":"2025082111222144900_bib5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025082111222144900_bib6","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2025082111222144900_bib7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","article-title":"Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression","volume":"104","author":"Seymour","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"2025082111222144900_bib8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bjh.17045","article-title":"Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"192","author":"Moccia","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"2025082111222144900_bib9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"2025082111222144900_bib10","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025082111222144900_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2025082111222144900_bib12","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"2025082111222144900_bib13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025082111222144900_bib14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/bloodadvances.2022007949","article-title":"Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy","volume":"7","author":"Rodr\u00edguez-Sevilla","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2025082111222144900_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.semnuclmed.2022.11.001","article-title":"PET\/CT in non-Hodgkin lymphoma: an update","volume":"53","author":"Zanoni","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"1","key":"2025082111222144900_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.annonc.2023.10.121","article-title":"Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial","volume":"35","author":"Cottereau","year":"2024","journal-title":"Ann Oncol"},{"issue":"35","key":"2025082111222144900_bib17","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025082111222144900_bib18","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025082111222144900_bib19","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"issue":"11","key":"2025082111222144900_bib20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025082111222144900_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"28","key":"2025082111222144900_bib22","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025082111222144900_bib23","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025082111222144900_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.18809","article-title":"Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort","volume":"202","author":"Le Goff","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"2025082111222144900_bib25","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2025082111222144900_bib26","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"key":"2025082111222144900_bib27","doi-asserted-by":"crossref","first-page":"870487","DOI":"10.3389\/fonc.2022.870487","article-title":"Plasma concentrations and cancer-associated mutations in cell-free circulating DNA of treatment-naive follicular lymphoma for improved non-invasive diagnosis and prognosis","volume":"12","author":"Hatipo\u011flu","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"2025082111222144900_bib28","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma","volume":"8","author":"Sarkozy","year":"2017.  31","journal-title":"Oncotarget"},{"issue":"3","key":"2025082111222144900_bib29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4143\/crt.2023.869","article-title":"Feasibility of circulating tumor DNA analysis in patients with follicular lymphoma","volume":"56","author":"Yoon","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"28","key":"2025082111222144900_bib30","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.22.00843","article-title":"Six-year results from RELEVANCE: lenalidomide plus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"2025082111222144900_bib31","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"1110","key":"2025082111222144900_bib32","first-page":"11.10.1","article-title":"From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinformatics"},{"key":"2025082111222144900_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-0716-2293-3_14","article-title":"UMI-Varcal: a low-frequency variant caller for UMI-tagged paired-end sequencing data","volume":"2493","author":"Sater","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"27","key":"2025082111222144900_bib34","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"2025082111222144900_bib35","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025082111222144900_bib40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41375-022-01803-x","article-title":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","volume":"37","author":"Jim\u00e9nez-Ubieto","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"2025082111222144900_bib36","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2967\/jnumed.121.262869","article-title":"Follicular lymphoma treated with first-fine immunochemotherapy: a review of PET\/CT in patients who did not achieve a complete metabolic response in the GALLIUM study","volume":"63","author":"Barrington","year":"2022","journal-title":"J Nucl Med"},{"issue":"5","key":"2025082111222144900_bib37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.23.00838","article-title":"Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM study","volume":"42","author":"Pott","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025082111222144900_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fern\u00e1ndez-Miranda","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/8\/913\/2407115\/blood_bld-2024-027727-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/8\/913\/2407115\/blood_bld-2024-027727-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:22:33Z","timestamp":1755789753000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/8\/913\/537744\/Combined-PET-and-ctDNA-response-as-a-predictor-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027727","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,21]]},"published":{"date-parts":[[2025,8,21]]}}}